GCP
FATE icon

GSA Capital Partners’s Fate Therapeutics FATE Stock Holding History

GSA Capital Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$303K Sell
112,267
-186,614
-62% -$345K 0.02% 1293
2026
Q1 		$359K Buy
298,881
+85,236
+40% +$104K 0.02% 1134
2025
Q4 		$210K Sell
213,645
-97,181
-31% -$117K 0.02% 1382
2025
Q3 		$392K Buy
310,826
+54,104
+21% +$58.3K 0.03% 1021
2025
Q2 		$288K Buy
+256,722
New +$298K 0.02% 1283
2024
Q3 		– Sell
-264,467
Closed -$867K – 1724
2024
Q2 		$867K Buy
264,467
+212,188
+406% +$929K 0.06% 598
2024
Q1 		$384K Buy
52,279
+9,276
+22% +$57.4K 0.03% 1066
2023
Q4 		$161K Sell
43,003
-210,426
-83% -$497K 0.01% 1363
2023
Q3 		$537K Buy
253,429
+59,019
+30% +$196K 0.05% 748
2023
Q2 		$925K Sell
194,410
-16,000
-8% -$88.3K 0.09% 356
2023
Q1 		$1.2M Buy
210,410
+151,978
+260% +$917K 0.12% 231
2022
Q4 		$590K Buy
+58,432
New +$1.1M 0.07% 502

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GSA Capital Partners's FATE Position: Q2 2026 in Review

GSA Capital Partners reduced its Fate Therapeutics (FATE) stake by 62% in Q2 2026, selling an estimated $345K and leaving 112,267 shares worth $303K. The position accounts for 0.02% of the portfolio, ranked #1293.

GSA Capital Partners first reported a position in FATE in Q4 2022 and has held it in 12 quarters since. The position peaked at $1.2M in Q1 2023. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • GSA Capital Partners held 112,267 shares of Fate Therapeutics worth $303K as of Q2 2026.
  • GSA Capital Partners sold 186,614 Fate Therapeutics shares in Q2 2026, an estimated $345K.
  • Fate Therapeutics made up 0.02% of GSA Capital Partners's portfolio in Q2 2026, its #1293 holding.
  • GSA Capital Partners first reported a position in Fate Therapeutics in Q4 2022 and has held it in 12 quarters since.
  • GSA Capital Partners's Fate Therapeutics position peaked at $1.2M in Q1 2023.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.